The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.
Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
Open accessAbstract
Antisense oligonucleotides (ASOs) bind sequence specifically to the target RNA and modulate protein expression through several different mechanisms. The ASO field is an emerging area of drug development that targets the disease source at the RNA level and offers a promising alternative to therapies targeting downstream processes. To translate ASO-based therapies into a clinical success, it is crucial to overcome the challenges associated with off-target side effects and insufficient biological activity. In this regard, several chemical modifications and diverse delivery strategies have been explored. In this review, we systematically discuss the chemical modifications, mechanism of action, and optimized delivery strategies of several different classes of ASOs. Further, we highlight the recent advances made in development of ASO-based drugs with a focus on drugs that are approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for clinical applications. We also discuss various promising ASO-based drug candidates in the clinical trials, and the outstanding opportunity of emerging microRNA as a viable therapeutic target for future ASO-based therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
The biogenesis, biology and characterization of circular RNAs
Kristensen, L. S., Andersen, M. S., Stagsted, L. V. W., Ebbesen, K. K., Hansen, T. B., & Kjems, J. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0158-7 · Cited by 4,823
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Wightman, B., Ha, I., & Ruvkun, G. (1993) · Cell · doi:10.1016/0092-8674(93)90530-4 · Cited by 4,292
Identification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,990
PLGA-based nanoparticles: An overview of biomedical applications
Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.043 · Cited by 3,806
Shah, M. A., Datson, N. A., Srinidhi, L., Stanton, V. P., MacDonald, M. E., Allard, M. W., Youngman, S., Am, F., Mott, R., Draths, K., et al. (1993) · Cell · Cited by 3,055
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Zamore, P. D., Tuschl, T., Sharp, P. A., & Bartel, D. P. (2000) · Cell · doi:10.1016/s0092-8674(00)80620-0 · Cited by 2,676
Walker, F. O. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60111-1 · Cited by 2,603
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., Chiriboga, C. A., Saito, K., Servais, L., Tizzano, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702752 · Cited by 2,337
Bushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., Cripe, L., Kaul, A., Kinnett, K., McDonald, C., Pandya, S., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70271-6 · Cited by 2,053
Prevalence of Muscular Dystrophies: A Systematic Literature Review
Theadom, A., Rodrigues, M., Roxburgh, R., Balalla, S., Higgins, C., Bhattacharjee, R., Jones, K., Krishnamurthi, R., & Feigin, V. (2014) · Neuroepidemiology · doi:10.1159/000369343 · Cited by 2,046
A germline-specific class of small RNAs binds mammalian Piwi proteins
Girard, A., Sachidanandam, R., Hannon, G. J., & Carmell, M. A. (2006) · Nature · doi:10.1038/nature04917 · Cited by 1,762
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis
Gibson, R. L., Burns, J. L., & Ramsey, B. W. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200304-505so · Cited by 1,633
The role of non-coding RNAs in oncology
Slack, F. J., & Chinnaiyan, A. M. (2019) · Cell · doi:10.1016/j.cell.2019.10.017 · Cited by 1,619
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Planté-Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,452
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
Mercuri, E., Darras, B. T., Chiriboga, C. A., Day, J. W., Campbell, C., Connolly, A. M., Iannaccone, S. T., Kirschner, J., Kuntz, N. L., Saito, K., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1710504 · Cited by 1,433
Cellular functions of long noncoding RNAs
Yao, R.-W., Wang, Y., & Chen, L.-L. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0311-8 · Cited by 1,386
Bennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374
Accumulation of miR-155 and BIC RNA in human B cell lymphomas
Eis, P. S., Tam, W., Sun, L., Chadburn, A., Li, Z., Gomez, M. F., Lund, E., & Dahlberg, J. E. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500613102 · Cited by 1,325
Liu, C., Zhou, Q., Li, Y., Garner, L. V., Watkins, S. P., Carter, L. J., Smoot, J., Gregg, A. C., Daniels, A. D., Jervey, S., et al. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00272 · Cited by 1,297
The chemical evolution of oligonucleotide therapies of clinical utility
Khvorova, A., & Watts, J. K. (2017) · Nature Biotechnology · doi:10.1038/nbt.3765 · Cited by 1,216
Passenger-Strand Cleavage Facilitates Assembly of siRNA into Ago2-Containing RNAi Enzyme Complexes
Matranga, C., Tomari, Y., Shin, C., Bartel, D. P., & Zamore, P. D. (2005) · Cell · doi:10.1016/j.cell.2005.08.044 · Cited by 1,211
MicroRNA in Control of Gene Expression: An Overview of Nuclear Functions
Catalanotto, C., Cogoni, C., & Zardo, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17101712 · Cited by 1,190
Overcoming cellular barriers for RNA therapeutics
Dowdy, S. F. (2017) · Nature Biotechnology · doi:10.1038/nbt.3802 · Cited by 1,139
Morpholino Antisense Oligomers: Design, Preparation, and Properties
SUMMERTON, J., & WELLER, D. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.187 · Cited by 1,116
The hemophilias--from royal genes to gene therapy
Mannucci, P. M., & Tuddenham, E. G. D. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106073442307 · Cited by 1,110
RNAi therapeutics: a potential new class of pharmaceutical drugs
Bumcrot, D., Manoharan, M., Koteliansky, V., & Sah, D. W. Y. (2006) · Nature Chemical Biology · doi:10.1038/nchembio839 · Cited by 1,085
Raal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M.-J., Cromwell, W. C., Lachmann, R. H., Gaudet, D., Tan, J. L., Chasan-Taber, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60284-x · Cited by 924
Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide.
Stephenson, M. L., & Zamecnik, P. C. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.285 · Cited by 906
Schiffelers, R. M. (2004) · Nucleic Acids Research · doi:10.1093/nar/gnh140 · Cited by 901
The delivery of therapeutic oligonucleotides
Juliano, R. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw236 · Cited by 854
Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
Kim, J., Hu, C., Moufawad El Achkar, C., Black, L. E., Douville, J., Larson, A., Pendergast, M. K., Goldkind, S. F., Lee, E. A., Kuniholm, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813279 · Cited by 827
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Raal, F. J., Kallend, D., Ray, K. K., Turner, T., Koenig, W., Wright, R. S., Wijngaard, P. L. J., Curcio, D., Jaros, M. J., Leiter, L. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913805 · Cited by 818
Antisense oligonucleotides: the next frontier for treatment of neurological disorders
Rinaldi, C., & Wood, M. J. A. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.148 · Cited by 788
Argonaute2 Cleaves the Anti-Guide Strand of siRNA during RISC Activation
Rand, T. A., Petersen, S., Du, F., & Wang, X. (2005) · Cell · doi:10.1016/j.cell.2005.10.020 · Cited by 784
Intravascular hemolysis and the pathophysiology of sickle cell disease
Kato, G. J., Steinberg, M. H., & Gladwin, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89741 · Cited by 748
Benjaminsen, R. V., Mattebjerg, M. A., Henriksen, J. R., Moghimi, S. M., & Andresen, T. L. (2013) · Molecular Therapy · doi:10.1038/mt.2012.185 · Cited by 735
Targeting Huntingtin Expression in Patients with Huntington’s Disease
Tabrizi, S. J., Leavitt, B. R., Landwehrmeyer, G. B., Wild, E. J., Saft, C., Barker, R. A., Blair, N. F., Craufurd, D., Priller, J., Rickards, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1900907 · Cited by 708
Freier, S. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.22.4429 · Cited by 692
Phosphorothioates, Essential Components of Therapeutic Oligonucleotides
Eckstein, F. (2014) · Nucleic Acid Therapeutics · doi:10.1089/nat.2014.0506 · Cited by 684
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
Witztum, J. L., Gaudet, D., Freedman, S. D., Alexander, V. J., Digenio, A., Williams, K. R., Yang, Q., Hughes, S. G., Geary, R. S., Arca, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1715944 · Cited by 669
Advances in the delivery of RNA therapeutics: from concept to clinical reality
Kaczmarek, J. C., Kowalski, P. S., & Anderson, D. G. (2017) · Genome Medicine · doi:10.1186/s13073-017-0450-0 · Cited by 656
Kinali, M., Arechavala-Gomeza, V., Feng, L., Cirak, S., Hunt, D., Adkin, C., Guglieri, M., Ashton, E., Abbs, S., Nihoyannopoulos, P., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70211-x · Cited by 653
Aberrant and Alternative Splicing in Cancer
Venables, J. P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1910 · Cited by 634
Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients
Goldberg, A. C., Hopkins, P. N., Toth, P. P., Ballantyne, C. M., Rader, D. J., Robinson, J. G., Daniels, S. R., Gidding, S. S., de Ferranti, S. D., Ito, M. K., et al. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.03.001 · Cited by 622
Genomic variants in exons and introns: identifying the splicing spoilers
Pagani, F., & Baralle, F. E. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1327 · Cited by 606
Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA
Braasch, D. A., & Corey, D. R. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00058-2 · Cited by 605
Lipid nanoparticles enabling gene therapies: from concepts to clinical utility
Kulkarni, J. A., Cullis, P. R., & van der Meel, R. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0721 · Cited by 592
Design of antisense oligonucleotides stabilized by locked nucleic acids
Kurreck, J. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.9.1911 · Cited by 577
Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.
Agrawal, S., Temsamani, J., & Tang, J. Y. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.17.7595 · Cited by 561
Passini, M. A., Bu, J., Richards, A. M., Kinnecom, C., Sardi, S. P., Stanek, L. M., Hua, Y., Rigo, F., Matson, J., Hung, G., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001777 · Cited by 547
Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients
Goldberg, A. C., Hopkins, P. N., Toth, P. P., Ballantyne, C. M., Rader, D. J., Robinson, J. G., Daniels, S. R., Gidding, S. S., de Ferranti, S. D., Ito, M. K., et al. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.04.003 · Cited by 545
Eteplirsen in the treatment of Duchenne muscular dystrophy
Lim, K. R., Maruyama, R., & Yokota, T. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s97635 · Cited by 495
Silencing disease genes in the laboratory and the clinic
Watts, J. K., & Corey, D. R. (2012) · The Journal of Pathology · doi:10.1002/path.2993 · Cited by 470
Pseudogenes: Pseudo-functional or key regulators in health and disease?
Pink, R. C., Wicks, K., Caley, D. P., Punch, E. K., Jacobs, L., & Francisco Carter, D. R. (2011) · RNA · doi:10.1261/rna.2658311 · Cited by 465
microRNA Therapeutics in Cancer — An Emerging Concept
Shah, M. Y., Ferrajoli, A., Sood, A. K., Lopez-Berestein, G., & Calin, G. A. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.09.017 · Cited by 453
Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease
Adams, D., Koike, H., Slama, M., & Coelho, T. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0210-4 · Cited by 448
Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides.
Dominski, Z., & Kole, R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8673 · Cited by 426
Pharmacology of Antisense Drugs
Bennett, C. F., Baker, B. F., Pham, N., Swayze, E., & Geary, R. S. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104846 · Cited by 425
Scott, L. J. (2020) · Drugs · doi:10.1007/s40265-020-01269-0 · Cited by 420
Gomez, I. G., MacKenna, D. A., Johnson, B. G., Kaimal, V., Roach, A. M., Ren, S., Nakagawa, N., Xin, C., Newitt, R., Pandya, S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci75852 · Cited by 413
Lu, Q. L., Rabinowitz, A., Chen, Y. C., Yokota, T., Yin, H., Alter, J., Jadoon, A., Bou-Gharios, G., & Partridge, T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406700102 · Cited by 402
Bissell, D. M., Anderson, K. E., & Bonkovsky, H. L. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1608634 · Cited by 399
Rehman, Z. U., Hoekstra, D., & Zuhorn, I. S. (2013) · ACS Nano · doi:10.1021/nn3049494 · Cited by 395
De Mesmaeker, A., Haener, R., Martin, P., & Moser, H. E. (1995) · Accounts of Chemical Research · doi:10.1021/ar00057a002 · Cited by 386
Phosphorothioate Oligodeoxynucleotides: What Is Their Origin and What Is Unique About Them?
ECKSTEIN, F. (2000) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.2000.10.117 · Cited by 382
FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga
Aartsma-Rus, A., & Krieg, A. M. (2017) · Nucleic Acid Therapeutics · doi:10.1089/nat.2016.0657 · Cited by 364
Molecular mechanisms of action of antisense drugs
Crooke, S. T. (1999) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(99)00148-7 · Cited by 358
Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense Drugs
Wu, H., Lima, W. F., Zhang, H., Fan, A., Sun, H., & Crooke, S. T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311683200 · Cited by 349
Spinal Muscular Atrophy: A Timely Review
Kolb, S. J. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.74 · Cited by 333
Seto, A. G., Beatty, X., Lynch, J. M., Hermreck, M., Tetzlaff, M., Duvic, M., & Jackson, A. L. (2018) · British Journal of Haematology · doi:10.1111/bjh.15547 · Cited by 333
Sekijima, Y. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308724 · Cited by 332
Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
Frank, D. E., Schnell, F. J., Akana, C., El-Husayni, S. H., Desjardins, C. A., Morgan, J., Charleston, J. S., Sardone, V., Domingos, J., Dickson, G., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009233 · Cited by 332
Progress in Antisense Oligonucleotide Therapeutics
Crooke, S. T., & Bennett, C. F. (1996) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.36.040196.000543 · Cited by 319
Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics
Huang, Y. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2016.12.003 · Cited by 291
A Simple γ-Backbone Modification Preorganizes Peptide Nucleic Acid into a Helical Structure
Dragulescu-Andrasi, A., Rapireddy, S., Frezza, B. M., Gayathri, C., Gil, R. R., & Ly, D. H. (2006) · Journal of the American Chemical Society · doi:10.1021/ja0625576 · Cited by 286
Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics
Lorenzer, C., Dirin, M., Winkler, A.-M., Baumann, V., & Winkler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.003 · Cited by 284
Rigo, F., Chun, S. J., Norris, D. A., Hung, G., Lee, S., Matson, J., Fey, R. A., Gaus, H., Hua, Y., Grundy, J. S., et al. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.212407 · Cited by 283
Clark, A. J., & Davis, M. E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1517048112 · Cited by 280
Resistance of Morpholino Phosphorodiamidate Oligomers to Enzymatic Degradation
HUDZIAK, R. M., BAROFSKY, E., BAROFSKY, D. F., WELLER, D. L., HUANG, S.-B., & WELLER, D. D. (1996) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1996.6.267 · Cited by 275
Pharmacokinetics of Antisense Oligonucleotides
Agrawal, S., Temsamani, J., Galbraith, W., & Tang, J. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199528010-00002 · Cited by 261
Finkbeiner, S. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a007476 · Cited by 255
Locked nucleic acid: modality, diversity, and drug discovery
Hagedorn, P. H., Persson, R., Funder, E. D., Albæk, N., Diemer, S. L., Hansen, D. J., Møller, M. R., Papargyri, N., Christiansen, H., Hansen, B. R., et al. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2017.09.018 · Cited by 238
Ottosen, S., Parsley, T. B., Yang, L., Zeh, K., van Doorn, L.-J., van der Veer, E., Raney, A. K., Hodges, M. R., & Patick, A. K. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04220-14 · Cited by 230
Kumar, V., Qin, J., Jiang, Y., Duncan, R. G., Brigham, B., Fishman, S., Nair, J. K., Akinc, A., Barros, S. A., & Kasperkovitz, P. V. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.61 · Cited by 222
The peptide nucleic acids (PNAs), powerful tools for molecular genetics and cytogenetics
Pellestor, F., & Paulasova, P. (2004) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201226 · Cited by 222
Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach
Mahmoodi Chalbatani, G., Dana, H., Gharagouzloo, E., Grijalvo, S., Eritja, R., Logsdon, C. D., Memari, F., Miri, S. R., Rezvani Rad, M., & Marmari, V. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s200253 · Cited by 221
McClorey, G., Moulton, H. M., Iversen, P. L., Fletcher, S., & Wilton, S. D. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302800 · Cited by 207
Antisense oligonucleotides: modifications and clinical trials
Sharma, V. K., Sharma, R. K., & Singh, S. K. (2014) · Med. Chem. Commun. · doi:10.1039/c4md00184b · Cited by 204
Azad, R. F., Driver, V. B., Tanaka, K., Crooke, R. M., & Anderson, K. P. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.9.1945 · Cited by 204
Zhu, X., Xu, Y., Solis, L. M., Tao, W., Wang, L., Behrens, C., Xu, X., Zhao, L., Liu, D., Wu, J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1505629112 · Cited by 203
Novel Binding and Efficient Cellular Uptake of Guanidine-Based Peptide Nucleic Acids (GPNA)
Zhou, P., Wang, M., Du, L., Fisher, G. W., Waggoner, A., & Ly, D. H. (2003) · Journal of the American Chemical Society · doi:10.1021/ja029665m · Cited by 202
(2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01327-2 · Cited by 199
Distinct Uptake Routes of Cell-Penetrating Peptide Conjugates
Lundin, P., Johansson, H., Guterstam, P., Holm, T., Hansen, M., Langel, Ü., & EL Andaloussi, S. (2008) · Bioconjugate Chemistry · doi:10.1021/bc800212j · Cited by 183
Furdon, P. J., Dominski, Z., & Kole, R. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.22.9193 · Cited by 176
Dá Mesquita, S., Ferreira, A. C., Sousa, J. C., Correia-Neves, M., Sousa, N., & Marques, F. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.06.014 · Cited by 166
Targeting RNA splicing for disease therapy
Havens, M. A., Duelli, D. M., & Hastings, M. L. (2013) · WIREs RNA · doi:10.1002/wrna.1158 · Cited by 163
Fomivirsen: Clinical Pharmacology and Potential Drug Interactions
Geary, R. S., Henry, S. P., & Grillone, L. R. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241040-00002 · Cited by 160
Mipomersen Sodium: First Global Approval
Hair, P., Cameron, F., & McKeage, K. (2013) · Drugs · doi:10.1007/s40265-013-0042-2 · Cited by 160
Targeting RNA : A Transformative Therapeutic Strategy
Yin, W., & Rogge, M. C. (2019) · Clinical and Translational Science · doi:10.1111/cts.12624 · Cited by 152
Therapeutic Potential of Splice-Switching Oligonucleotides
Bauman, J. A., Jearawiriyapaisarn, N., & Kole, R. (2009) · Oligonucleotides · doi:10.1089/oli.2008.0161 · Cited by 150
Hua, Y., Liu, Y. H., Sahashi, K., Rigo, F., Bennett, C. F., & Krainer, A. R. (2015) · Genes & Development · doi:10.1101/gad.256644.114 · Cited by 148
Toward a more complete view of tRNA biology
Giegé, R. (2008) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1498 · Cited by 138
van Deventer, S. J. H., Wedel, M. K., Baker, B. F., Xia, S., Chuang, E., & Miner, P. B. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02910.x · Cited by 127
Intrathecal administration of nusinersen in adolescent and adult SMA type 2 and 3 patients
Wurster, C. D., Winter, B., Wollinsky, K. H., Ludolph, A. C., Uzelac, Ž., Witzel, S., Schocke, M. F. H., Schneider, R., & Kocak, T. (2018) · Journal of Neurology · doi:10.1007/s00415-018-9124-0 · Cited by 122
Expression of Asialoglycoprotein Receptor 1 in Human Hepatocellular Carcinoma
Shi, B., Abrams, M. T., & Sepp‐Lorenzino, L. (2013) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155413503662 · Cited by 119
Cell and molecular biology of transthyretin and thyroid hormones
Richardson, S. J. (2007) · International Review of Cytology · doi:10.1016/s0074-7696(07)58003-4 · Cited by 116
Shen, W., Hoyos, C. L. D., Sun, H., Vickers, T. A., Liang, X., & Crooke, S. T. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky060 · Cited by 115
Devi, G. R., Beer, T. M., Corless, C. L., Arora, V., Weller, D. L., & Iversen, P. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2091 · Cited by 111
An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B
Machin, N., & Ragni, M. V. (2018) · Journal of Blood Medicine · doi:10.2147/jbm.s159297 · Cited by 111
Antiinfective Applications of Toll-like Receptor 9 Agonists
KRIEG, A. M. (2007) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200701-021aw · Cited by 104
Spurgers, K. B., Sharkey, C. M., Warfield, K. L., & Bavari, S. (2008) · Antiviral Research · doi:10.1016/j.antiviral.2007.12.008 · Cited by 100
Dias, N., Dheur, S., Nielsen, P. E., Gryaznov, S. M., Aerschot, A. A. V., Herdewijn, P. A., Hélène, C., & Saison-Behmoaras, T. E. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3277 · Cited by 96
The application of antisense oligonucleotide technology to the brain: Some pitfalls
Chiasson, B. J., Armstrong, J. N., Hooper, M. L., Murphy, P. R., & Robertson, H. A. (1994) · Cellular and Molecular Neurobiology · doi:10.1007/bf02088834 · Cited by 92
Exon-Skipping Antisense Oligonucleotides to Correct Missplicing in Neurogenetic Diseases
Siva, K., Covello, G., & Denti, M. A. (2014) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.0461 · Cited by 92
Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides
Ward, A. J., Norrbom, M., Chun, S. J., Bennett, C. F., & Rigo, F. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku184 · Cited by 87
RNA repair restores hemoglobin expression in IVS2–654 thalassemic mice
Svasti, S., Suwanmanee, T., Fucharoen, S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812436106 · Cited by 79
Molecular basis of familial hypercholesterolemia.
Russell, D. W., Esser, V., & Hobbs, H. H. (1989) · PubMed · Cited by 76
van der Wal, E., Bergsma, A. J., Pijnenburg, J. M., van der Ploeg, A. T., & Pijnappel, W. W. M. P. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.03.001 · Cited by 72
PLGA-based dual targeted nanoparticles enhance miRNA transfection efficiency in hepatic carcinoma
Cai, C., Xie, Y., Wu, L., Chen, X., Liu, H., Zhou, Y., Zou, H., Liu, D., Zhao, Y., Kong, X., et al. (2017) · Scientific Reports · doi:10.1038/srep46250 · Cited by 62
Ortega, J.-A., Blas, J. R., Orozco, M., Grandas, A., Pedroso, E., & Robles, J. (2007) · Organic Letters · doi:10.1021/ol701826x · Cited by 61
Rapireddy, S., Bahal, R., & Ly, D. H. (2011) · Biochemistry · doi:10.1021/bi2002554 · Cited by 60
Self-citationChenna, V., Rapireddy, S., Sahu, B., Ausín, C., Pedroso, E., & Ly, D. H. (2008) · ChemBioChem · doi:10.1002/cbic.200800441 · Cited by 59
Marrosu, E., Ala, P., Muntoni, F., & Zhou, H. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.07.006 · Cited by 50
Hebb, M. O., & Robertson, H. A. (1997) · Molecular Brain Research · doi:10.1016/s0169-328x(97)00048-x · Cited by 48
Belfort, R., Da, G., Johnson, D. W., Mansour, S., Muccioli, C., Sheppard, J., Mora-Durate, J., Chan, C., Palestine, A., Perez, J. E. A., et al. (2002) · UCL Discovery (University College London) · Cited by 41
Molecular basis of familial hypercholesterolemia
Bruikman, C. S., Hovingh, G. K., & Kastelein, J. J. P. (2017) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000385 · Cited by 38
Oligonucleotides and the COVID-19 Pandemic: A Perspective
Rossi, J. J., & Rossi, D. (2020) · Nucleic Acid Therapeutics · doi:10.1089/nat.2020.0868 · Cited by 31
Peptide nucleic acids harness dual information codes in a single molecule
Swenson, C., & Heemstra, J. M. (2020) · Chemical Communications · doi:10.1039/c9cc09905k · Cited by 26
Shilling, R. A., Karsten, V., Silliman, N., Chen, J., Li, W., & Vest, J. (2020) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(20)34206-6 · Cited by 13
Cited by
Gene regulation by long non-coding RNAs and its biological functions
Statello, L., Guo, C.-J., Chen, L.-L., & Huarte, M. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00315-9 · Cited by 4,991
Drug delivery systems for RNA therapeutics
Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349
Trials and Tribulations of MicroRNA Therapeutics
Seyhan, A. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031469 · Cited by 381
Lin, W., Chen, Y., Unadkat, J. D., Zhang, X., Wu, D., & Heimbach, T. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03274-2 · Cited by 137
Momin, M. Y., Gaddam, R. R., Kravitz, M., Gupta, A., & Vikram, A. (2021) · Cells · doi:10.3390/cells10113097 · Cited by 107
Self-citation
Metadata
- Authors
- Dhuri, K., Bechtold, C., Quijano, E., Pham, H., Gupta, A., Vikram, A., & Bahal, R.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2020-06-26
- Volume
- 9
- Issue
- 6
- Pages
- 2004
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W3037517625
- Cited by
- 545
- References
- 134
- FWCI
- 15.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.